Compare DUOT & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | NBP |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 212.8M |
| IPO Year | 2017 | N/A |
| Metric | DUOT | NBP |
|---|---|---|
| Price | $13.77 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $17.00 | $9.00 |
| AVG Volume (30 Days) | 828.9K | ★ 870.2K |
| Earning Date | 05-14-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,023,651.00 | N/A |
| Revenue This Year | $50.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 271.16 | N/A |
| 52 Week Low | $5.78 | $1.67 |
| 52 Week High | $15.28 | $5.19 |
| Indicator | DUOT | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 68.08 | 27.20 |
| Support Level | $8.12 | $1.67 |
| Resistance Level | N/A | $1.95 |
| Average True Range (ATR) | 1.22 | 0.11 |
| MACD | 0.44 | 0.01 |
| Stochastic Oscillator | 80.36 | 13.46 |
Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.